If these tumours are ≥T2, or spread to lymph nodes, chemotherapy is preferred in neoadjuvant settings with anthracycline-taxane combined with dual HER2 blockade (trastuzumab and petruzumab). This evidence concerns the gene ERBB2 and neoplasm.